Brokers Issue Forecasts for AXSM Q3 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at B. Riley issued their Q3 2025 EPS estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Tuesday, September 30th. B. Riley analyst M. El-Saadi anticipates that the company will post earnings per share of ($1.16) for the quarter. B. Riley currently has a “Buy” rating and a $179.00 price target on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Axsome Therapeutics’ Q4 2025 earnings at ($1.07) EPS, FY2025 earnings at ($4.07) EPS, FY2026 earnings at $0.60 EPS, FY2027 earnings at $8.00 EPS, FY2028 earnings at $17.66 EPS and FY2029 earnings at $24.58 EPS.

Several other research analysts have also commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $150.00 price target on shares of Axsome Therapeutics in a research report on Monday, August 4th. Bank of America increased their target price on Axsome Therapeutics from $173.00 to $176.00 and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Wells Fargo & Company raised shares of Axsome Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 3rd. Royal Bank Of Canada raised their target price on shares of Axsome Therapeutics from $184.00 to $189.00 and gave the company an “outperform” rating in a research report on Tuesday, August 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $180.00 target price on shares of Axsome Therapeutics in a research note on Tuesday, June 10th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $177.93.

Axsome Therapeutics Trading Up 0.3%

Shares of NASDAQ:AXSM opened at $120.30 on Friday. The company has a current ratio of 1.57, a quick ratio of 1.51 and a debt-to-equity ratio of 1.66. Axsome Therapeutics has a 12-month low of $75.56 and a 12-month high of $139.13. The company has a market cap of $6.00 billion, a PE ratio of -23.73 and a beta of 0.52. The stock has a 50 day moving average of $114.94 and a 200 day moving average of $110.07.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Monday, August 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.08. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. The company had revenue of $150.04 million during the quarter, compared to analysts’ expectations of $140.02 million.

Insider Activity

In other Axsome Therapeutics news, Director Roger Jeffs sold 13,464 shares of Axsome Therapeutics stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $123.68, for a total value of $1,665,227.52. Following the completion of the transaction, the director owned 57,510 shares of the company’s stock, valued at $7,112,836.80. The trade was a 18.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, COO Mark L. Jacobson sold 10,000 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $115.96, for a total value of $1,159,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 197,948 shares of company stock worth $23,406,686 over the last three months. 22.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BVF Inc. IL boosted its holdings in Axsome Therapeutics by 21.8% during the first quarter. BVF Inc. IL now owns 1,690,221 shares of the company’s stock worth $197,130,000 after buying an additional 302,157 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Axsome Therapeutics by 5.8% in the second quarter. Geode Capital Management LLC now owns 989,453 shares of the company’s stock worth $103,303,000 after acquiring an additional 54,600 shares in the last quarter. State Street Corp boosted its stake in Axsome Therapeutics by 5.8% in the 2nd quarter. State Street Corp now owns 958,503 shares of the company’s stock worth $100,058,000 after purchasing an additional 52,483 shares during the period. Invesco Ltd. grew its position in Axsome Therapeutics by 23.8% during the 1st quarter. Invesco Ltd. now owns 857,001 shares of the company’s stock worth $99,952,000 after purchasing an additional 164,537 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in Axsome Therapeutics by 41.1% during the 2nd quarter. Bank of America Corp DE now owns 753,429 shares of the company’s stock valued at $78,650,000 after purchasing an additional 219,527 shares during the period. 81.49% of the stock is owned by institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.